2016 Email Cribbage Tournament begins Sunday, May 1st

The 2016 Email Cribbage Tournament is about to begin!

Your Chapter must be registered on or before Sunday, May 1, 2016. The closing date for the tournament is Friday, May 27, 2016.

To register and receive the necessary forms please contact:

Bill Rizzo, Chair, National Tournaments

Phone: 613-549-6196         E-mail : [email protected]

Information packages will be sent out to you immediately following your request.

Nova Scotia Health Authority (Central Zone) Diversity Bursary: Deadline February 5, 2016

The Nova Scotia Health Authority (Central Zone)  is taking steps to create a more diverse workforce that better represents the communities we serve. Post-secondary students who identify as African Nova Scotian, Aboriginal, immigrant or a person with a disability are invited to apply for a diversity bursary. Students must be:

  • Continuing studies in a health profession
  • Attending a Canadian post-secondary institution that is recognized by the Association of Universities and Colleges of Canada
  • A resident of Halifax Regional Municipality or West Hants with an intention to practice in the area.


Applications are available at  http://www.cdha.nshealth.ca/diversity-inclusion.  For more information please contact Anna Jacobs, [email protected], (902) 460-6888.

Applications will be evaluated by Community Health Boards on a number of factors including: community involvement, financial need, educational goals and field of study in health care.

Treatment Access for Canadians Living with Wet Age-Related Macular Degeneration May be Restricted

Treatment Access for Canadians Living with Wet Age-Related Macular Degeneration May be Restricted

Do you have age-related macular degeneration (AMD)? Then, this story matters to you. Do you care about fair and equitable access to safe medications? Then, this story matters to you too.

This story matters to Canadians living with AMD because regulators are getting ready to make recommendations that could restrict access to sight-saving drugs across the country. But, this is also a much bigger story that matters to all Canadians because this particular regulatory decision would set a new precedent regarding the use of off-label medications.

Because this is such an important decision, the Foundation Fighting Blindness has been working closely with the CNIB and the Canadian Council of the Blind to be sure that patients’ perspectives and experiences factor into the decision making process. Today, we are sharing this update because we want our communities to know that we have taken a firm stance together and have formally asked the regulators to suspend their decision making process until adequate safety data is available.

Inequitable Treatment across Canada

Age-related macular degeneration (AMD) is the leading cause of blindness in people over the age of 50. There are two forms of AMD – dry AMD and wet AMD. Dry AMD is the most common form of the disease and is characterized by the gradual loss of central vision. Sometimes, this dry form of AMD will progress into the wet form of AMD, which is when most vision loss occurs. Wet AMD can have a sudden onset and is characterized by abnormal blood vessel growth in the eye. Fortunately, there are effective sight-saving treatments for wet AMD called anti-VEGF drugs. Vascular endothelial growth factor (VEGF) is normally produced in our bodies and is involved in the growth of blood vessels. However, the uncontrolled growth of blood vessels in the eye causes vision loss in wet AMD. Anti-VEGF therapies prevent (and even reverse) vision loss by removing excess VEGF from the eye. In Canada, there are two anti-VEGF drugs, Lucentis (ranibizumab) and Eylea (aflibercept), which have been approved to treat a variety of retinal diseases, including wet AMD. Avastin (bevacizumab) is an anti-VEGF drug that was designed to treat cancer, but is used “off-label” to treat retinal diseases.

Notably, Avastin is significantly cheaper than both Lucentis and Eylea. In addition, some studies have shown that is functions effectively as a sight-saving treatment. For these reasons, many doctors have opted to use Avastin as a first line of treatment, especially when their patients cannot afford the alternative.

Who pays for your medications?

In Canada, we consider health care to be right. Across the country, many of us are fortunate to receive excellent medical care, paid for by Canadian taxpayers. Accessing medically necessary drugs, however, is less straightforward. Some people have private insurance while others depend on publicly funded drug programs, such as the Ontario Public Drug Program, which is widely used by people over the age of 65.

If the public drug program in your province covers the drugs that you need, then everything usually works out well. Unfortunately, not all drugs are covered, and different provinces cover different drugs. This means that you have access to different drugs depending on where you live. In Alberta, for example, the newest anti-VEGF drug for treating wet-age related macular degeneration (Eylea) is not covered by the public drug program.

Comparing Different Treatment Options to “Optimize” the Approach

Regardless of where you live, your access to anti-VEGF drugs to treat retinal diseases, including wet AMD, is at risk. This is because the Canadian Agency for Drugs and Technologies in Health (CADTH) is currently evaluating the monetary cost and clinical efficacy of different anti-VEGF drugs (including Lucentis, Eylea and Avastin). They are conducting this “Therapeutic Review” with the goal of making recommendations to “optimize” how these drugs are covered by provincial drug plans. The word “optimization” is used to signify that decision makers are looking for ways to save money without having a negative impact on health outcomes. Optimization implies that decisions are being made within constraints; for example, each province has a limited amount of money to spend on its public drug program. If you are interested in the fine details of the review, you can learn more on the CADTH website.

In brief, CADTH is conducting this review because they realize that the prevalence of people living with wet AMD and other retinal diseases will increase significantly as the population ages, and they are aware that Avastin is considerably less expensive than the other anti-VEGF drugs. (Avastin is an anti-VEGF drug that was developed to treat cancer, but is sometimes used “off-label” to treat wet AMD.) In addition, there are now some results from clinical studies that compare the effectiveness of the different available anti-VEGF drugs.

Patient Evidence Matters

At the beginning of this review process, the Foundation Fighting Blindness was invited by CADTH to submit patient evidence. To do this, we collaborated with the CNIB and the Canadian Council of the Blind to share the experiences of people who are taking anti-VEGF drugs to treat their eye diseases. To learn more, we developed a short survey and invited people to share their stories. Thank you to everyone who provided feedback!! Because of you, we were able to develop a patient evidence submission that contained a diversity of experiences with voices from across country.

In the patient submission, we emphasized that patients care about safe and equitable access to drugs. We told CADTH that some people were having difficult experiences in British Columbia, where access is more restrained. We told CADTH that although many people shared positive experiences with taking anti-VEGF drugs, others also shared more negative experiences. Because people had different experiences with different anti-VEGF drugs, we emphasized the importance of patient choice. You can read the full collaborative submission of patient evidence on the CADTH website here.

Recently, CADTH released a “Draft Science Report” that summarized the evidence that they considered (including our patient submission). As a patient group, we were invited to provide feedback on this Draft Report.

After reading the Draft Science Report, we were all surprised for two reasons. First, the report seemed to misinterpret the patient evidence that we submitted. Second, even though the report repeatedly acknowledged the lack of available safety data, it concluded that the drugs have equivalent safety risks. To us, this was a red flag because safety is so important to patients. In fact, sufficient safety data is a necessary criterion for embarking on a Therapeutic Review.

For these reasons, we have asked CADTH to suspend making any further recommendations until there is sufficient safety data available to justify the analysis. We sincerely hope that CADTH will consider our feedback because we believe that patient evidence is an essential component to effective decision making for the health of Canadians.

Your voice still matters. Please take the AMD survey or call to let us know about your experiences with anti-VEGF drugs. There will be additional opportunities for patient input before a decision is made. As a patient group, our job is to bring your voice to the table. We are honored to have this responsibility.

Vocal Eye

Vocaleye descriptive arts society

is a non-profit organization located in vancouver, bc. we describe theatre, arts and culture for those with vision loss.

Click on a newsletter at the left to read.

About Live Audio Description

VocalEye’s Live Audio Description Program is the first of its kind in Canada. Originally a program of Kickstart Disability Arts and Culture, our professionally trained describers provide the visual details of live theatre performance to blind and low vision audiences in Vancouver, Richmond, Surrey and Victoria, BC.

Theatre patrons with vision loss are given a personal receiver with a single earpiece and volume control that allows them to hear both the show and our live audio description at the same time. Our live transmission begins ten minutes before curtain with brief descriptions of the set, characters and costumes. Once the show begins, our describer transmits pertinent physical action and visual information between the lines of dialogue. Short program notes and additional description for the second act may be provided at intermission.

Mandate & Mission

VocalEye Descriptive Arts Society exists to serve individuals of all ages with vision loss in our community by:

~ providing accessible description of live theatre and other arts and cultural events

~ lowering barriers to participation in theatre, arts and cultural events

~ promoting access to theatre, arts and cultural events through education and outreach

Our Services

  • Described theatre performances for adults and young audiences in Vancouver, Richmond, Surrey and Victoria, BC
  • Advance description, program notes and plot synopses in accessible formats
  • Touch Tours: guided tactile experiences of the production’s sets, props and costumes
  • Theatre Buddies: volunteer guides to and from the theatre
  • Sighted Guide Training: workshops in guiding techniques
  • Live Audio Subtitling
  • Described Performance Training
  • Equipment rental for description or translation purposes

For more information on our descriptive services, training or equipment rental, please submit your enquiry to  [email protected]

In Development

  • Live Audio Description of Dance, Opera and Festivals
  • Verbal Description of Visual Art for public art tours, galleries and museums
  • Vancouver Beyond Sight: Verbal Description of Landmarks and Architecture
  • Community Workshops in Arts and Culture for those with vision loss

For updates on all our activities and events, please join our mailing list by completing the form in the sidebar under “Subscribe” or please send an email to  [email protected] with “subscribe” in the subject line.


The first Live Audio Description program in Canada (called “EarSighted”) was launched by Kickstart Disability Arts and Culture at the Vancouver Playhouse Theatre Company’s production of The Miracle Worker in 2009. The following year, the team was invited to describe a number of performances for the 2010 Vancouver Cultural Olympics, including Robert LePage’s Blue Dragon.

The program was renamed “VocalEye” in 2011 and following two successful seasons became a separate non-profit society in 2012 and a Chapter of The Canadian Council of the Blind BC/Yukon, a registered charity, in 2013. VocalEye Descriptive Arts continues to provide a full season of described theatre performance in Vancouver, the Lower Mainland and Victoria. Other descriptive services and programs serving the blind and partially sighted community are currently in development.

Life after vision loss

Life after vision loss

Louise Gillis begins third term as president of national organization, represents Canada at international level

As president of the Canadian Council of the Blind, Louise Gillis is busy throughout the year attending meetings across the country and dealing with council business and responding to emails from her home in Sydney. LAURA JEAN GRANT – COMMUNITY POST



SYDNEY — “There is life after vision loss.”

It’s a statement that Cape Bre- ton’s Louise Gillis not only strong- ly believes, it’s something she’s demonstrated day in and day out for decades.

Originally from Skye Glen, Inverness County, Gillis has called Sydney home for the last 40 years. About two years after settling in Sydney, where she was working as a nurse,   Gillis’ eye troubles first developed…..   Read the Rest by downloading the PDF 

Translate »